Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Hennika, Tammy ^a   Hu, Guo ^a   Olaciregui, Nagore G ^b,c   Barton, Kelly L ^a   Ehteda, Anahid ^d   Chitranjan, Arjanna ^d   Chang, Cecilia ^d   Gifford, Andrew J ^d,e   Tsoli, Maria ^d   Ziegler, David S ^d,f   Carcaboso, Angel M ^b,c   Becher, Oren J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Preclinical Therapeutics and Drug Delivery Research Program   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; HISTONE DEACETYLASE; HISTONE H3; PANOBINOSTAT; PLATELET DERIVED GROWTH FACTOR B; PROTEIN P53; VIMENTIN; HISTONE; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ENZYME INHIBITION; GENETICALLY ENGINEERED MOUSE STRAIN; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PONTINE GLIOMA; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; TREATMENT DURATION; ACETYLATION; ANIMAL; BRAIN CORTEX; BRAIN STEM NEOPLASMS; C57BL MOUSE; CELL CLONE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENETIC ENGINEERING; GLIOMA; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ACETYLATION; ANIMALS; APOPTOSIS; BRAIN STEM NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CEREBRAL CORTEX; CLONE CELLS; GENETIC ENGINEERING; GLIOMA; HISTONES; HUMANS; HYDROXAMIC ACIDS; INDOLES; INHIBITORY CONCENTRATION 50; MICE, INBRED C57BL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008319032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169485     Document Type: Article

References (27)

1. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. The Lancet Oncology. 2006; 7(3): 241-8. doi: 10.1016/S1470-2045(06)70615-5 PMID: 16510333
2. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. International journal of radiation oncology, biology, physics. 1998; 40(2): 265-71. PMID: 9457808
3. Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatric research. 2014; 75(1-2): 205-9. doi: 10.1038/pr.2013.194 PMID: 24192697
4. Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. Journal of neuro-oncology. 2014; 119(1): 7-15. doi: 10.1007/s11060-014-1448-8 PMID: 24792486
5. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature genetics. 2012; 44(3): 251-3. PubMed Central PMCID: PMC3288377. doi: 10.1038/ng.1102 PMID: 22286216
6. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384): 226-31. doi: 10.1038/nature10833 PMID: 22286061
7. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature genetics. 2014; 46(5): 444-50. PubMed Central PMCID: PMC4056452. doi: 10.1038/ng.2938 PMID: 24705251
8. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature genetics. 2014; 46(5): 451-6. PubMed Central PMCID: PMC3997489. doi: 10.1038/ng.2936 PMID: 24705254
9. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature genetics. 2014; 46(5): 462-6. PubMed Central PMCID: PMC4282994. doi: 10.1038/ng.2950 PMID: 24705250
10. Taylor KR, Vinci M, Bullock AN, Jones C. ACVR1 mutations in DIPG: lessons learned from FOP. Cancer research. 2014; 74(17): 4565-70 PubMed Central PMCID: PMC4154859. doi: 10.1158/0008-5472.CAN-14-1298 PMID: 25136070
11. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature genetics. 2014; 46(5): 457-61. PubMed Central PMCID: PMCPMC4018681. doi: 10.1038/ng.2925 PMID: 24705252
12. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta neuropathologica. 2012; 124(3): 439-47. PubMed Central PMCID: PMC3422615. doi: 10.1007/s00401-012-0998-0 PMID: 22661320
13. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer cell. 2012; 22(4): 425-37. doi: 10.1016/j.ccr.2012.08.024 PMID: 23079654
14. Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134): 857-61 PubMed Central PMCID: PMC3951439. doi: 10.1126/science.1232245 PMID: 23539183
15. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer cell. 2013; 24(5): 660-72. doi: 10.1016/j.ccr.2013.10.006 PMID: 24183680
16. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes & development. 2013; 27 (9): 985-90. PubMed Central PMCID: PMC3656328.
17. Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, et al. Histone H3F3Aand HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta neuropathologica. 2015; 130(6): 815-27. PubMed Central PMCID: PMCPMC4654747. doi: 10.1007/s00401-015-1478-0 PMID: 26399631
18. Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016; 7: 11185. PubMed Central PMCID: PMCPMC4823825. doi: 10.1038/ncomms11185 PMID: 27048880
19. New M, Olzscha H, La Thangue NB HDAC inhibitor-based therapies: can we interpret the code? Molecular oncology. 2012; 6(6): 637-56 doi: 10.1016/j.molonc.2012.09.003 PMID: 23141799
20. Anne M, Sammartino D, Barginear MF, Budman D. Profile of panobinostat and its potential for treatment in solid tumors: an update. OncoTargets and therapy. 2013; 6: 1613-24. PubMed Central PMCID: PMC3833618. doi: 10.2147/OTT.S30773 PMID: 24265556
21. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nature medicine. 2015; 21(6): 555-9. doi: 10.1038/nm.3855 PMID: 25939062
22. Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, et al. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PloS one. 2015; 10(3): e0118926. PubMed Central PMCID: PMCPMC4352073. doi: 10.1371/journal.pone.0118926 PMID: 25748921
23. Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PloS one. 2013; 8(10): e77639. PubMed Central PMCID: PMC3788718. doi: 10.1371/journal.pone.0077639 PMID: 24098593
24. Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011; 108(11): 4453-8. PubMed Central PMCID: PMCPMC3060250. doi: 10.1073/pnas.1101657108 PMID: 21368213
25. Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, et al. ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B driven brainstem glioma model. Molecular cancer therapeutics. 2016.
26. Subashi E, Cordero FJ, Halvorson KG, Qi Y, Nouls JC, Becher OJ, et al. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma. Journal of neuro-oncology. 2016; 126(2): 243-51. PubMed Central PMCID: PMC4720569. doi: 10.1007/s11060-015-1969-9 PMID: 26511492
27. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert review of neurotherapeutics. 2009; 9(10): 1519-27. PubMed Central PMCID: PMC3657605. doi: 10.1586/ern.09.99 PMID: 19831841